Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-25

Clinical Trial Update: Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab [Phase 1, Phase 2]

View source ↗

Summary

A safety study of a helper peptide vaccine in combination with pembrolizumab in melanoma has completed phases 1 and 2 with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Helper peptide vaccine
  • Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-25